Literature DB >> 15889449

Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility.

Shireen Sirhan1, Virgil F Fairbanks, Ayalew Tefferi.   

Abstract

BACKGROUND: Despite the absence of any systematic evidence for diagnostic utility, red cell mass (RCM) measurement has been endorsed as a major diagnostic criterion for polycythemia vera (PV) based on a set of eligibility criteria for a clinical trial formulated by an International PV Study Group in 1967.
METHODS: A retrospective analysis was performed on a consecutive series of 105 patients who underwent blood volume measurements for evaluation of polycythemia. In a previous study, the authors had systematically compared RCM measurement by 51Cr-labeled erythrocytes and 125I-labeled human serum albumin and demonstrated equivalence between the two methods. In the current study, they used the latter method and applied the International Committee for Standardization in Haematology recommendations for result interpretation in order to evaluate test performance and practical utility.
RESULTS: RCM exceeded the 98-99% limits of the reference range in 76%, 20%, 22%, and 57% of patients with PV (n = 25), secondary polycythemia (n = 35), spurious or apparent polycythemia (n = 38), and essential thrombocythemia (n = 7), respectively. Decreased plasma volume was rarely seen in any of the disease categories. In all instances of PV, the diagnosis was readily apparent, based on alternative clinical and laboratory tests, and did not require the additional information from blood volume measurement. Furthermore, alternative methods of PV diagnosis, based on disease-specific biological markers as well as bone marrow histology, are now available.
CONCLUSIONS: The continued use of RCM and plasma volume measurements for the diagnosis of PV is no longer warranted.

Entities:  

Mesh:

Year:  2005        PMID: 15889449     DOI: 10.1002/cncr.21105

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 2.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

Review 3.  A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F).

Authors:  Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 4.  Polycythaemia vera and essential thrombocythaemia: current treatment strategies.

Authors:  Elisabeth I Penninga; Ole W Bjerrum
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  How I treat essential thrombocythemia.

Authors:  Philip A Beer; Wendy N Erber; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

6.  Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia.

Authors:  Mihir Raval; Anu Paul
Journal:  Case Rep Neurol       Date:  2010-11-22

7.  Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.

Authors:  Soo-Mee Bang; Jeong Yeal Ahn; Jiyoon Park; Soo Jin Yoo; Se Hoon Park; Eun Mi Nam; Pil Whan Park; Yiel Hea Seo; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Korean J Intern Med       Date:  2006-12       Impact factor: 2.884

8.  A Case of Uncorrected Tetralogy of Fallot Undiagnosed Until Adulthood and Presenting With Polycythemia.

Authors:  Ercan Gunduz; Ahmet Gorgel; Recep Dursun; Hasan Mansur Durgun; Habip Cil; Mustafa Icer; Yilmaz Zengin
Journal:  Cardiol Res       Date:  2014-12-04

Review 9.  JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.

Authors:  Naseema Gangat; Natasha Szuber; Animesh Pardanani; Ayalew Tefferi
Journal:  Leukemia       Date:  2021-05-21       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.